Raymond James Financial Cuts Humana (NYSE:HUM) Price Target to $230.00

Humana (NYSE:HUM) had its target price lowered by Raymond James Financial from $340.00 to $230.00 in a research report sent to investors on Friday morning,MarketScreener reports. Raymond James Financial currently has an outperform rating on the insurance provider’s stock.

Other equities analysts have also recently issued reports about the company. Zacks Research cut Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Evercore ISI lowered their target price on Humana from $260.00 to $180.00 in a report on Thursday. Guggenheim cut their price target on shares of Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research note on Thursday. Wolfe Research increased their price target on shares of Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Finally, Truist Financial dropped their price objective on shares of Humana from $300.00 to $285.00 and set a “hold” rating for the company in a report on Monday, November 10th. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $238.29.

Humana Trading Up 2.8%

Shares of Humana stock opened at $183.92 on Friday. The company has a current ratio of 2.00, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70. Humana has a twelve month low of $169.61 and a twelve month high of $315.35. The firm has a market capitalization of $22.12 billion, a PE ratio of 18.73, a P/E/G ratio of 1.96 and a beta of 0.44. The firm’s 50-day moving average price is $244.65 and its 200 day moving average price is $261.02.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the prior year, the company earned ($2.16) EPS. The firm’s revenue was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, sell-side analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Institutional Trading of Humana

Institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors increased its holdings in shares of Humana by 113.9% in the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Humana by 273.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock worth $907,541,000 after acquiring an additional 2,553,509 shares during the last quarter. Norges Bank acquired a new stake in shares of Humana during the fourth quarter valued at $456,632,000. Franklin Resources Inc. grew its holdings in shares of Humana by 914.5% during the fourth quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider’s stock worth $321,613,000 after buying an additional 1,131,893 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Humana by 161.5% in the third quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock valued at $446,911,000 after buying an additional 1,060,767 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.